<?xml version="1.0" encoding="utf-8"?>
<Journal>
<Journal-Info>
<name>International Journal of Pharma and Bio Sciences</name>
<website>ijpbs.net</website>
<email>editorijpbs@rediffmail.com (or) editorofijpbs@yahoo.com (or) prasmol@rediffmail.com</email>
</Journal-Info>
<article>
<article-id pub-id-type='other'>10.22376/ijpbs.2019.10.1.p1-12</article-id>
<issue_number>Volume 8 Issue 2</issue_number>
<issue_period>2017 (April - June)</issue_period>
<title><b>Targeting visceral leishmaniasis by mannosylated liposome incorporated pitc-2 isolated from the plant <i>pluchea indica</i> (L) less.</b> <b>(Funded Work)</b></title>
<abstract>Leishmaniasis is a vector borne disease, endemic in large populated areas. PITC-2 is a natural compound, isolated from evergreen herb  lessThan i greaterThan Pluchea indica lessThan /i greaterThan (L.) Less. Animal studies have revealed that PITC-2 is non-toxic. The primary objective of this study was to demonstrate the possible increase in efficacy of mannosylated derivatives of PITC-2 in leishmania infected hamsters. The efficiencies of intercalated and mannose grafted liposomes of PITC-2 were found to be 37.24% and 31.25%, respectively, with the molar ratio of phosphatidylcholine, cholesterol and PITC-2 being 9:1:1. In  lessThan i greaterThan in vitro lessThan /i greaterThan  studies liposomes in excised rat skin indicated slow release and penetration of PITC-2 liposomes. PITC-2 showed a significant anti-leishmanial activity against promastigotes (extracellular) of parasite  lessThan i greaterThan Leishmania donovani in lessThan /i greaterThan   lessThan i greaterThan vitro lessThan /i greaterThan . The IC lessThan sub greaterThan 50 lessThan /sub greaterThan  of PITC-2 was 1.095 µg. The efficacies o f PITC-2 liposomes were tested against experimental leishmaniasis in mice and hamster models in three different forms: free PITC-2, Liposome intercalated and mannose grafted liposome of PITC-2. Efficacy of PITC-2 was significantly improved with mannose grafted liposome, as demonstrated by 88.30 % (in mice model) and 84.27% (in hamster model) reduction of splenic parasitic burden, respectively and 74.81% (in mice model) and 80.21% (in hamster model) reduction of liver parasitic burden, respectively. Histology of spleen and selected liver function tests (Alkaline phosphatase, SGPT and SGOT in blood plasma) indicated that the toxicity of PITC-2 was comparable to controls in mannosylated liposome incorporated PITC-2 animals. Although the drug release profile did not differ much the mannose grafted PITC-2 encapsulated liposomes were found to be effective in significantly lowering splenic and liver parasitic loads without toxicity.</abstract>
<authors>SHARMILY CHAKRABORTY &amp; TAPAN KUMAR CHATTERJEE</authors>
<keywords>Leishmaniasis, Parasite burden, Mannosylated liposome, Drug release.</keywords>
<pages>396-408</pages>
</article>
</Journal>
